| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/09/2023 | 30.52% | Needham | $9 → $6.5 | Maintains | Buy |
| 08/11/2023 | 20.48% | Wedbush | $8 → $6 | Maintains | Outperform |
| 08/10/2023 | 80.72% | Needham | $10 → $9 | Maintains | Buy |
| 05/10/2023 | 100.8% | Needham | $12 → $10 | Maintains | Buy |
| 03/09/2023 | 140.96% | Needham | $14.25 → $12 | Maintains | Buy |
| 03/09/2023 | 642.97% | Cantor Fitzgerald | $41 → $37 | Maintains | Overweight |
| 03/06/2023 | 723.29% | Cantor Fitzgerald | $51 → $41 | Maintains | Overweight |
| 12/02/2022 | 261.45% | Wedbush | → $18 | Initiates Coverage On | → Outperform |
| 11/10/2022 | 924.1% | Cantor Fitzgerald | $54 → $51 | Maintains | Overweight |
| 08/11/2022 | 984.34% | Cantor Fitzgerald | $57 → $54 | Maintains | Overweight |
| 07/22/2022 | 361.85% | Seaport Global | → $23 | Initiates Coverage On | → Buy |
| 05/13/2022 | 1044.58% | Cantor Fitzgerald | $59 → $57 | Maintains | Overweight |
| 03/31/2022 | 843.78% | Needham | $50 → $47 | Maintains | Buy |
| 03/29/2022 | 1104.82% | Cantor Fitzgerald | $72 → $60 | Maintains | Overweight |
| 02/18/2022 | 904.02% | Needham | $54 → $50 | Maintains | Buy |
| 01/07/2022 | — | Wolfe Research | Initiates Coverage On | → Outperform | |
| 12/06/2021 | 1345.78% | Cantor Fitzgerald | $73 → $72 | Maintains | Overweight |
| 11/03/2021 | 1365.86% | Cantor Fitzgerald | $77 → $73 | Maintains | Overweight |
| 09/22/2021 | 1526.51% | Cantor Fitzgerald | $50.5 → $81 | Maintains | Overweight |
| 08/05/2021 | 1270.48% | Needham | $62.25 → $68.25 | Maintains | Buy |
| 07/07/2021 | 1144.98% | Jefferies | → $62 | Initiates Coverage On | → Buy |
| 05/14/2021 | 1325.7% | Cantor Fitzgerald | $76 → $71 | Maintains | Overweight |
| 05/10/2021 | 1426.1% | Cantor Fitzgerald | $89 → $76 | Maintains | Overweight |
| 04/30/2021 | 1687.15% | Cantor Fitzgerald | $83 → $89 | Maintains | Overweight |
| 03/24/2021 | 1119.88% | Needham | $60.5 → $60.75 | Maintains | Buy |
| 02/04/2021 | 1104.82% | Roth Capital | → $60 | Initiates Coverage On | → Buy |
| 11/17/2020 | 1165.06% | Cantor Fitzgerald | $60 → $63 | Maintains | Overweight |
| 09/17/2020 | 1104.82% | Cantor Fitzgerald | $59 → $60 | Maintains | Overweight |
| 08/04/2020 | 487.35% | Needham | $18.2 → $29.25 | Maintains | Buy |
| 06/30/2020 | 944.18% | Cantor Fitzgerald | $50 → $52 | Maintains | Overweight |
| 05/21/2020 | 265.46% | Needham | $17.2 → $18.2 | Maintains | Buy |
| 05/13/2020 | 245.38% | Needham | $15.5 → $17.2 | Maintains | Buy |
| 04/09/2020 | 211.24% | Needham | $15.25 → $15.5 | Maintains | Buy |
| 04/06/2020 | 502.41% | Cantor Fitzgerald | $32 → $30 | Maintains | Overweight |
| 03/23/2020 | 206.22% | Needham | $20 → $15.25 | Maintains | Buy |
| 02/14/2020 | 502.41% | Cantor Fitzgerald | → $30 | Initiates Coverage On | → Overweight |
| 12/16/2019 | 301.61% | Craig-Hallum | → $20 | Initiates Coverage On | → Buy |
| 12/03/2019 | 301.61% | Needham | → $20 | Initiates Coverage On | → Buy |
| 12/02/2019 | 241.37% | Compass Point | $11 → $17 | Upgrades | Neutral → Buy |
What is the target price for Trulieve Cannabis (TCNNF)?
The latest price target for Trulieve Cannabis (OTCQX: TCNNF) was reported by Needham on November 9, 2023. The analyst firm set a price target for $6.50 expecting TCNNF to rise to within 12 months (a possible 30.52% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Trulieve Cannabis (TCNNF)?
The latest analyst rating for Trulieve Cannabis (OTCQX: TCNNF) was provided by Needham, and Trulieve Cannabis maintained their buy rating.
When is the next analyst rating going to be posted or updated for Trulieve Cannabis (TCNNF)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Trulieve Cannabis, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Trulieve Cannabis was filed on November 9, 2023 so you should expect the next rating to be made available sometime around November 9, 2024.
Is the Analyst Rating Trulieve Cannabis (TCNNF) correct?
While ratings are subjective and will change, the latest Trulieve Cannabis (TCNNF) rating was a maintained with a price target of $9.00 to $6.50. The current price Trulieve Cannabis (TCNNF) is trading at is $4.98, which is out of the analyst's predicted range.
